Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects

NCT07246252 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers (HV)

Interventions

BIOLOGICAL: Process-Changed CMAB007
BIOLOGICAL: Xolair (omalizumab)

Sponsor

Taizhou Mabtech Pharmaceutical Co.,Ltd